Appendix 1A — ASX Listing Application and Agreement is required by listing rule 1.7 to be used by an entity seeking admission to the official list as an ASX Listing.
View Appendix 1A — ASX Listing Application and Agreement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)